Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 50 of 2536

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Pegzilarginase for treating arginase-1 deficiency in people 2 years and overHST35
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancerTA1138
Rare diseasesQS214
Blood transfusionQS138
Molnupiravir for treating COVID-19TA1056
Hypertension in adults: diagnosis and managementNG136
Blood transfusionNG24
Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19TA878
Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancerTA1136
Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TA1137
Leadless cardiac pacemaker implantation for bradyarrhythmiasHTG770
Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitationHTG771
Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal)TA1135
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myelomaTA1133
Dupilumab for treating severe chronic rhinosinusitis with nasal polypsTA1134
Type 2 diabetes in adults: managementNG28
Type 2 diabetes in adultsQS209
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2HST34
Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal)TA1132
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1129
Obinutuzumab with mycophenolate mofetil for treating lupus nephritisTA1131
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancerTA1130
Pulmonary artery pressure technologies for remote monitoring of chronic heart failureHTG769
Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancerTA1127
Targeted-release budesonide for treating primary IgA nephropathyTA1128
Digital technologies to support self-management of COPD: early value assessmentHTG736
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapyTA1126
Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)TA1124
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal)TA1125
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early value assessmentHTG766
Digital self-help for eating disorders: early value assessmentHTG768
Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)TA1123
Balloon cryoablation for Barrett's oesophagusHTG767
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1122
Acoramidis for treating transthyretin amyloidosis with cardiomyopathyTA1121
Suspected cancer: recognition and referralNG12
Avelumab with axitinib for untreated advanced renal cell carcinomaTA1120
Overweight and obesity managementNG246
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)TA1118
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaTA1119
VA ECMO for postcardiotomy cardiogenic shock in adultsHTG762
DMD Care UK's guideline on respiratory care: NICE reviewNR2
Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiencyTA1117
Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemiaTA1116
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathyTA1115
Digital platforms to support cardiac rehabilitation: early value assessmentHTG761
Child maltreatment: when to suspect maltreatment in under 18sCG89
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphomaTA1113
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1114

Results per page

  1. 10
  2. 25
  3. 50
  4. All